SGEN Chart

1 Month

	Date	Diff
	2023-12-22
The article discusses the recent downtrend in biotech stocks and the factors that may contribute to a brighter outlook for the sector in 2024, including a more favorable interest-rate outlook, increased deal activity, and innovations in areas like cancer and immunology. The decline in interest in riskier small-cap biotechs due to rising interest rates and regulatory concerns has impacted the sector in recent years. However, analysts believe that with a more dovish stance from the Federal Reserve and increased comfort around regulatory issues, investors' risk appetite for biotech stocks may increase. Additionally, major pharmaceutical companies with cash reserves and a need for innovative drugs are expected to drive mergers and acquisitions in the biotech sector in 2024. The article also highlights some companies that analysts see as potential targets or favorites for 2024, including Merus NV, Disc Medicine Inc., Viking Therapeutics Inc., and Amgen Inc. The article states that drugmaker Bristol Myers Squibb is acquiring biopharmaceutical company Karuna Therapeutics for $14 billion in a deal that offers a premium of 53% over Karuna's stock price. The acquisition is expected to enhance Bristol Myers Squibb's growth through the development of Karuna's experimental antipsychotic, KarXT, and strengthen its neuroscience portfolio. The stock price of Bristol Myers Squibb has been down year-to-date, similar to other large drugmakers in 2023. The transaction is subject to regulatory approvals and is expected to close in the first half of 2024. Drugmaker Bristol Myers Squibb is acquiring Karuna Therapeutics for $14 billion in a deal that offers a premium of 53% over Karuna's stock, with the acquisition expected to enhance Bristol Myers Squibb's growth through the late 2020s and into the next decade; shares of Bristol Myers Squibb are up about 2% in afternoon trading, but down more than 27% year-to-date.
	2023-12-21
The article discusses the decline in Seagen (SGEN) stock and suggests that the decrease might be attributed to Pfizer's shift in focus away from COVID-19 drugs and towards potential deals, share buybacks, and new treatments in its pipeline, leading to uncertainty among investors.
	2023-12-20
The article discusses the benefits of dividend stocks for income and growth investors, but does not provide information on why Seagen (SGEN) stock specifically went down last night. The article discusses the 12 best stocks to buy on Robinhood for beginners and highlights Seagen (SGEN) as one of them, but doesn't explain why the stock went down.
	2023-12-19
The article discusses the healthcare sector and the changing landscape of the industry. The healthcare sector has been performing poorly in 2023, with the Health Care Select Sector SPDR Fund declining by 1.24% year-to-date. According to Jim Cramer, the healthcare sector is facing challenges due to the US government's focus on healthcare policies and lack of innovation in the sector. However, some healthcare stocks have performed well, including companies in the biotech industry. The article also highlights several promising healthcare stocks according to analysts, including AstraZeneca PLC, argenx SE, Biogen Inc., Alnylam Pharmaceuticals, The Cigna Group, Takeda Pharmaceutical Company Limited, and Incyte Corporation. Seagen (SGEN) stock went down by 0.0% last night, and the reason for the decline is not mentioned in the article. The article is about the performance of Seagen (SGEN) stock, which was down 0.0% last night; the reason for the decline is not provided in the given information.
	2023-12-18
Shares of Pfizer are down due to a forecasted revenue slump in 2024, which is attributed to declining demand for the company's COVID-19 vaccine and related products. Pfizer's stock decline is also influenced by a decrease in demand for Moderna's drugs, suggesting a potential decline in the pharmaceutical industry overall.
	2023-12-15
The article discusses the approval of Keytruda in combination with Padcev to treat bladder cancer, which resulted in a slight decrease in Seagen's stock price. The stock may have gone down due to concerns about competition in the market or overall market conditions.
	2023-12-14	-0.07 %
The Seagen (SGEN) stock went down by 0.07% last night, but the article does not provide a specific reason for this decline. The article announces the appointment of Clay Siegall, the former CEO and President of Seagen (SGEN), as Chairman of the Board of Tourmaline Bio, a biotechnology company. The reason for Seagen stock going down is not mentioned in the article. The article announces that Pfizer has completed its acquisition of Seagen Inc. and highlights the potential for Pfizer's Oncology portfolio to contribute to the company's financial goals, but it does not specifically mention why Seagen stock went down.
	2023-12-13	-0.07 %
The Seagen (SGEN) stock went down by -0.07% last night, likely due to Pfizer's disappointing 2024 guidance and reduced COVID sales expectations. Pfizer expects 2024 revenue and earnings per share to be lower than analyst expectations, causing a decline in its own stock and impacting other COVID-vaccine makers like Moderna and Novavax. The article discusses the recent decline in Pfizer (PFE) stock and attributes it to the market's lack of interest in value and yield, as well as disappointment over Pfizer's 2024 revenue and earnings guidance. The article suggests that Pfizer stock may be a good contrarian play for investors looking for a potential recovery. The decline in Seagen (SGEN) stock is not mentioned in the article. The Seagen (SGEN) stock went down last night as Pfizer's revised revenue figures, which included Seagen, fell below the consensus target, disappointing investors.
	2023-12-12	+3.29 %
Pfizer has received all regulatory approvals for its $43 billion acquisition of biotech cancer specialist Seagen, and the stock went up 3.29% likely due to the news that the U.S. antitrust waiting period has expired and Pfizer has agreed to donate royalties from U.S. sales of the cancer drug Bavencio to the American Association for Cancer Research. Pfizer is set to close its $43 billion acquisition of Seagen Inc., a cancer drugmaker, which will enhance its oncology portfolio and create a new oncology division within Pfizer. The stock price of Seagen increased by 3.3% on the news of the acquisition. The article discusses the regulatory approvals received by Pfizer to close its acquisition of Seagen, and the decision to donate the rights of royalties from sales of its cancer drug Bavencio to address antitrust concerns. The reason for the increase in Seagen's stock is not mentioned in the article.
	2023-12-07	+1.17 %
The article discusses the upsides and downsides of a growth strategy by acquisition in business. The Seagen (SGEN) stock went up last night, but the article does not provide a specific reason for this increase.
	2023-11-30	-0.15 %
The biotech stocks rose on Thursday as AbbVie announced plans to acquire cancer drug developer ImmunoGen for $10.1 billion, causing shares of ImmunoGen to close nearly 83% higher and AbbVie's stock to close almost 3% higher, while other biotech companies developing similar drugs also saw their stock prices increase. This news did not directly impact Seagen (SGEN) stock, which went down by -0.15% last night, but the article does not provide a specific reason for Seagen's decrease in stock price.
	2023-11-29	-0.3 %
The article is about Pfizer's CFO, Dave Denton, speaking at the Evercore ISI HealthCONx Conference. Regarding Seagen's stock going down, the article does not provide any specific information or explanation for the decline.
	2023-11-09	-0.39 %
Seagen (SGEN) stock went down by -0.39% last night, likely due to the challenging economic environment, rising cost of capital, and cautious investor sentiment in the biotechnology sector, as well as disappointing trial results from some companies in Seagen's portfolio.
	2023-11-07	-0.14 %
The article discusses Genmab's regulatory approvals in Japan and Europe for its medicine EPKINLY/TEPKINLY and provides an update on the company's financial performance. The reason for Seagen (SGEN) stock going down is not mentioned in the article.
	2023-11-01	+0.73 %
Pfizer is laying off more staff, particularly in its New Jersey facility, due to poor Covid vaccine sales, but Wall Street is optimistic about the company's future plans, including its acquisition of cancer therapy producer Seagen, which is expected to close in late 2023 or early 2024, and the development of its oral obesity pill. While Pfizer's stock has dropped this year, investors see potential in its pipeline of products. Seagen (SGEN) stock went up by 0.73% last night, likely due to positive market conditions and investor optimism. Seagen Inc. (SGEN) reported strong financial results for the third quarter, with record net product sales of $571 million, primarily driven by the success of its PADCEV drug in combination with Keytruda for the treatment of advanced urothelial cancer. The company also announced positive trial results across its commercial portfolio and expressed excitement about its pending acquisition by Pfizer. The stock went up because of the strong sales performance and the potential for the PADCEV drug to become a new standard of care in the treatment of metastatic bladder cancer.
	2023-10-31	-0.63 %
Seagen (SGEN) stock went down by -0.63% following Pfizer's weak demand for its COVID-19 vaccine and treatment, resulting in the drugmaker's first quarterly loss since 2019; analysts predict that the drop in vaccine and product usage as the pandemic recedes will continue to drag down Pfizer's shares. The article reports that Seagen (SGEN) stock was down 0.63% last night, but the reason for the decline is not mentioned in the article. The article primarily provides financial updates and guidance for Pfizer Inc. (PFE) for the third quarter of 2023, including revenue numbers and earnings per share.
	2023-10-26	-0.44 %
Seagen (SGEN) stock went down 0.44% last night, but the article does not provide a specific reason for this decrease.
	2023-10-23	+0.64 %
Seagen (SGEN) stock went up by 0.64% after positive test results for an experimental bladder cancer treatment by Merck (MRK) and Seagen, with over two-thirds of patients responding to the treatment.
	2023-10-19	+0.06 %
In a recent announcement, biotechnology company Immunome, Inc. appointed Dr. Bob Lechleider as Chief Medical Officer, which is expected to add value to the company's vision of developing targeted cancer therapies; the stock of Seagen (SGEN) went up 0.06% last night. The article reports that Pfizer has received unconditional approval from the European Union for its $43 billion acquisition of cancer drug maker Seagen, and the stock went up by 0.06%. The EU antitrust watchdog stated that the merger would not raise competition concerns.
	2023-10-17	+0.2 %
The article highlights that Seagen (SGEN) stock has outperformed the market over the past 5 years with an average annual return of 24.8%, and currently has a market capitalization of $40.45 billion. The reason for the recent 0.2% increase in Seagen stock is not mentioned in the summary.
	2023-10-16	+0.41 %
The article discusses Pfizer's cost-cutting program and lowered revenue guidance due to underwhelming COVID-19 product sales, which had a negative impact on the company's stock price. However, Pfizer executives expressed hope for future vaccination rates through combined respiratory vaccines and reassured investors that the cost-cutting program will not impact the planned acquisition of Seagen Inc. Seagen's stock price went up, possibly due to investors finding comfort in Pfizer's update. The article discusses how Pfizer's stock has declined by nearly 40% in 2023 due to declining revenues from weaker COVID-19 vaccine sales. The decline in Pfizer's stock is likely attributed to the expected decrease in sales of its COVID-19 products. The article mentions that Pfizer's stock is currently trading just above a 3-year support level, and losing this threshold could lead to further drops in the stock price. Additionally, the article mentions Pfizer's recent acquisition of cancer treatment specialist Seagen. It does not mention the reason for Seagen's stock going up.
	2023-10-11	+0.05 %
The article discusses Petrie Partners, a boutique advisory firm, which advised on the Pioneer Natural Resources Co's $60 billion sale to Exxon Mobil, alongside major investment banks. The fees from this transaction are expected to benefit Goldman Sachs Group and Citigroup Inc. Seagen Inc's previous sale to Pfizer Inc resulted in Centerview receiving $88 million in fees, and Guggenheim Securities received $49 million. The article mentions that megadeals have been infrequent due to regulatory scrutiny, high interest rates, and market volatility. Overall, the article does not explain why Seagen (SGEN) stock went up by 0.05%. The article discusses Exxon Mobil's plan to acquire Pioneer Natural Resources for $64.5 billion, making it the largest merger announced in 2023 so far, with the deal being an all-stock transaction. The stock price of Exxon Mobil was down by 4.4% while Pioneer Natural Resources went up by 0.9%. The use of all-stock deals is relatively rare, but it makes sense for Exxon Mobil given the uncertainty in the macroeconomic environment and the volatility of commodity markets. The company's stock price has tripled in the past three years, making it a good time to use stock as currency for the acquisition. The article does not mention anything about Seagen (SGEN) stock going up.
	2023-10-05	+0.02 %
The article discusses the positive results from the Phase 3 AMBASSADOR trial, which evaluated Merck's anti-PD-1 therapy, KEYTRUDA, as adjuvant treatment for patients with localized muscle-invasive urothelial carcinoma and locally advanced urothelial carcinoma, leading to a 0.02% increase in Seagen stock.
	2023-10-03	+0.36 %
The article announces that Clay B. Siegall, former co-founder and CEO of Seagen, Inc., has been appointed as Chairman and CEO, and discusses a completed $125 million private placement investment that will support the company's expected cash runway. The article also mentions that Seagen expects to submit three investigational new drug applications (INDs) within 18 months. The reason for the stock going up is not explicitly stated in the article.
	2023-09-22	+3.54 %
Seagen (SGEN) stock went up 3.54% last night, and the reason for the increase is not mentioned in the given article. Seattle Genetics (SGEN) stock rose 3.5% after the company reported positive results from a clinical trial for patients with previously untreated bladder cancer, showing improved survival compared to chemotherapy.
	2023-09-18	-0.59 %
The article announces that John Orwin has been appointed as chairman of AnaptysBio's Board of Directors, and mentions his experience in the biopharmaceutical industry. The article does not provide any information about the reason for the decline in Seagen (SGEN) stock. The article does not provide any information about Seagen (SGEN) stock or the reason behind its decline. It primarily focuses on Pfizer's conference call and provides information about the webcast and access details.
	2023-09-15	+0.92 %
The European Commission will decide on Pfizer's $43 billion bid for Seagen by October 19th, and the stock went up due to the positive news of the potential deal.
	2023-09-07	-0.58 %
Seagen (SGEN) stock went down last night, and the reason for the decrease in stock price is not mentioned in the article.
	2023-09-06	-0.52 %
The article is about LAVA Therapeutics participating in a virtual fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference, and provides information about the company's immuno-oncology platform and ongoing clinical studies. There is no information provided about Seagen (SGEN) stock or why it went down.
	2023-08-29	+0.34 %
Seagen (SGEN) stock went up 0.34% last night after market observers are confident that Amgen will complete its $28 billion takeover of Horizon Therapeutics following the US Federal Trade Commission's decision to allow a proposed settlement that would avoid further litigation, indicating a high probability of the deal closing sooner.
	2023-08-28	+3.23 %
Seagen (SGEN) stock went up by 3.23% after the Federal Trade Commission paused its case to block Amgen Inc.'s takeover of Horizon Therapeutics, signaling a high probability that the deal will close and potentially improving the overall tone for mergers and acquisitions in the pharmaceutical sector.
	2023-08-22	+0.51 %
The article discusses the strong performance of large drugmakers in the second quarter of 2023, with companies beating earnings and sales estimates. This has led to an increase in investor interest in the pharmaceutical sector. Innovation, successful pipeline developments, aggressive M&A activity, and collaborations are driving the growth of these companies. As for Seagen (SGEN) stock, it is mentioned that Pfizer has offered to buy Seagen for $43 billion, which is expected to close in late 2023 or early 2024. The article discusses the recent trend of M&A activity in the biotech industry and provides a list of 11 undervalued biotech stocks to buy according to analysts. The reason for the increase in Seagen (SGEN) stock is not specified in the article.
	2023-08-17	-0.23 %
The article discusses the current performance of the biotech sector, highlighting that despite major news and M&A activity, biotech stocks have not seen much improvement in terms of stock performances in 2023, with many trading in the red. The reason for this lack of momentum is attributed to investors' preference for technology stocks fueled by AI, strict regulatory environments around drug prices, and the high failure rate of new drugs.
	2023-08-16	-0.44 %
Seagen Inc. (SGEN) announced that its Phase 3 clinical trial of TUKYSA in combination with Kadcyla has met its primary endpoint of progression-free survival in patients with HER2-positive breast cancer, but the stock went down because adverse events and discontinuations were more common in the combination arm of the trial, raising concerns about safety.
	2023-08-09	+0.1 %
Novavax, a pharmaceutical company, saw its stock price increase by 0.1% after posting better-than-expected earnings for the second quarter, showing a net income of $58 million and sales of $424.4 million; however, the company still faces challenges as it revised its full-year revenue forecast and continues to cut costs through a restructuring plan.
	2023-08-08	+0.52 %
The article discusses two high-yield dividend stocks, Pfizer and Gilead Sciences, which have seen their stock prices decline recently but are still worth considering for investors. Pfizer's stock has dropped due to the market's anticipation of the declining demand for its COVID-19 vaccine, but the company has made strategic acquisitions, such as Seagen, and partnerships to ensure future growth. Gilead Sciences has experienced a decline in sales from its COVID-19 antiviral but remains a leader in the HIV market and has a promising oncology segment. Both companies offer attractive dividend yields and have a track record of increasing dividends.
	2023-08-01	+0.35 %
The article mentions that Pfizer's stock fell 1.7% after the company's second-quarter earnings declined due to lower sales of its COVID vaccine. The reason for Seagen (SGEN) stock going up is not provided in the article.
	2023-07-14	+0.43 %
The article reports that the US Federal Trade Commission has requested more information and documents regarding Pfizer's planned acquisition of Seagen Inc, which may have caused Seagen's stock to go up by 0.43% last night.
	2023-07-12	+0.51 %
Seagen Inc. (SGEN) stock went up by 0.51% last night, but the article does not provide a specific reason for the increase.
	2023-07-05	-0.53 %
The article reports that Teva Pharmaceutical Industries Ltd. is considering options for its active ingredients business, including a potential sale, as the company aims to gauge interest from potential buyers in the unit, which could be valued at about $2 billion; the reason for seagen (SGEN) stock going down is not mentioned in the article.